Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

DNA Damage Response and Oxidative Stress in Systemic Autoimmunity.

Souliotis VL, Vlachogiannis NI, Pappa M, Argyriou A, Ntouros PA, Sfikakis PP.

Int J Mol Sci. 2019 Dec 20;21(1). pii: E55. doi: 10.3390/ijms21010055. Review.

2.

DNA damage accumulation, defective chromatin organization and deficient DNA repair capacity in patients with rheumatoid arthritis.

Souliotis VL, Vlachogiannis NI, Pappa M, Argyriou A, Sfikakis PP.

Clin Immunol. 2019 Jun;203:28-36. doi: 10.1016/j.clim.2019.03.009. Epub 2019 Mar 28.

PMID:
30930144
3.

Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability.

Galanos P, Pappas G, Polyzos A, Kotsinas A, Svolaki I, Giakoumakis NN, Glytsou C, Pateras IS, Swain U, Souliotis VL, Georgakilas AG, Geacintov N, Scorrano L, Lukas C, Lukas J, Livneh Z, Lygerou Z, Chowdhury D, Sørensen CS, Bartek J, Gorgoulis VG.

Genome Biol. 2018 Mar 16;19(1):37. doi: 10.1186/s13059-018-1401-9.

4.

MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome.

Fragkioudaki S, Nezos A, Souliotis VL, Chatziandreou I, Saetta AA, Drakoulis N, Tzioufas AG, Voulgarelis M, Sfikakis PP, Koutsilieris M, Crow MK, Moutsopoulos HM, Mavragani CP.

Sci Rep. 2017 Aug 4;7(1):7354. doi: 10.1038/s41598-017-07347-w.

5.

Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus.

Souliotis VL, Vougas K, Gorgoulis VG, Sfikakis PP.

Arthritis Res Ther. 2016 Aug 4;18(1):182. doi: 10.1186/s13075-016-1081-3.

6.

DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.

Gkotzamanidou M, Terpos E, Bamia C, Munshi NC, Dimopoulos MA, Souliotis VL.

Blood. 2016 Sep 1;128(9):1214-25. doi: 10.1182/blood-2016-01-691618. Epub 2016 Jul 21.

7.

Benzo[a]pyrene-induced cell cycle arrest in HepG2 cells is associated with delayed induction of mitotic instability.

Stellas D, Souliotis VL, Bekyrou M, Smirlis D, Kirsch-Volders M, Degrassi F, Cundari E, Kyrtopoulos SA.

Mutat Res. 2014 Nov;769:59-68. doi: 10.1016/j.mrfmmm.2014.07.004. Epub 2014 Jul 19.

PMID:
25771725
8.

Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.

Stefanou DT, Bamias A, Episkopou H, Kyrtopoulos SA, Likka M, Kalampokas T, Photiou S, Gavalas N, Sfikakis PP, Dimopoulos MA, Souliotis VL.

PLoS One. 2015 Feb 6;10(2):e0117654. doi: 10.1371/journal.pone.0117654. eCollection 2015.

9.

Increased DNA double-strand breaks and enhanced apoptosis in patients with lupus nephritis.

Souliotis VL, Sfikakis PP.

Lupus. 2015 Jul;24(8):804-15. doi: 10.1177/0961203314565413. Epub 2014 Dec 26.

PMID:
25542905
10.

Adduct levels from benzo[a]pyrenediol epoxide: Relative formation to histidine in serum albumin and to deoxyguanosine in DNA in vitro and in vivo in mice measured by LC/MS-MS methods.

Westberg EA, Singh R, Hedebrant U, Koukouves G, Souliotis VL, Farmer PB, Segerbäck D, Kyrtopoulos S, Törnqvist MÅ.

Toxicol Lett. 2015 Jan 5;232(1):28-36. doi: 10.1016/j.toxlet.2014.09.019. Epub 2014 Sep 26.

PMID:
25261590
11.

Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Gkotzamanidou M, Sfikakis PP, Kyrtopoulos SA, Bamia C, Dimopoulos MA, Souliotis VL.

Br J Cancer. 2014 Sep 23;111(7):1293-304. doi: 10.1038/bjc.2014.410. Epub 2014 Jul 22.

12.

Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.

Gkotzamanidou M, Christoulas D, Souliotis VL, Papatheodorou A, Dimopoulos MA, Terpos E.

Med Sci Monit. 2013 Dec 20;19:1188-94. doi: 10.12659/MSM.889752.

13.

Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Gkotzamanidou M, Terpos E, Bamia C, Kyrtopoulos SA, Sfikakis PP, Dimopoulos MA, Souliotis VL.

Leukemia. 2014 May;28(5):1113-21. doi: 10.1038/leu.2013.284. Epub 2013 Oct 3.

PMID:
24089038
14.

Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs.

Stefanou DT, Episkopou H, Kyrtopoulos SA, Bamias A, Gkotzamanidou M, Bamia C, Liakou C, Bekyrou M, Sfikakis PP, Dimopoulos MA, Souliotis VL.

Br J Clin Pharmacol. 2012 Nov;74(5):842-53. doi: 10.1111/j.1365-2125.2012.04274.x.

15.

The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect.

Episkopou H, Kyrtopoulos SA, Sfikakis PP, Dimopoulos MA, Souliotis VL.

Mutat Res. 2011 Sep 1;714(1-2):78-87. doi: 10.1016/j.mrfmmm.2011.06.012. Epub 2011 Jul 6.

PMID:
21762707
16.

Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts.

Episkopou H, Kyrtopoulos SA, Sfikakis PP, Fousteri M, Dimopoulos MA, Mullenders LH, Souliotis VL.

Cancer Res. 2009 May 15;69(10):4424-33. doi: 10.1158/0008-5472.CAN-08-3489. Epub 2009 May 5.

17.

Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma.

Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos E, Kyrtopoulos SA, Sfikakis PP.

Haematologica. 2007 Nov;92(11):1505-12.

18.

Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.

Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN.

Clin Immunol. 2007 Apr;123(1):66-73. Epub 2007 Jan 31.

PMID:
17275413
19.

Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.

Souliotis VL, Dimopoulos MA, Episkopou HG, Kyrtopoulos SA, Sfikakis PP.

DNA Repair (Amst). 2006 Aug 13;5(8):972-85. Epub 2006 Jun 15.

PMID:
16781199
20.

Detection and quantitation of benzo[a]pyrene-derived DNA adducts in mouse liver by liquid chromatography-tandem mass spectrometry: comparison with 32P-postlabeling.

Singh R, Gaskell M, Le Pla RC, Kaur B, Azim-Araghi A, Roach J, Koukouves G, Souliotis VL, Kyrtopoulos SA, Farmer PB.

Chem Res Toxicol. 2006 Jun;19(6):868-78.

PMID:
16780367
21.
22.

Intra- and intercellular variations in the repair efficiency of O6-methylguanine, and their contribution to kinetic complexity.

Souliotis VL, Sfikakis PP, Anderson LM, Kyrtopoulos SA.

Mutat Res. 2004 Dec 21;568(2):155-70.

PMID:
15542103
23.
24.

Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus.

Katsiari CG, Liossis SN, Souliotis VL, Dimopoulos AM, Manoussakis MN, Sfikakis PP.

Clin Immunol. 2002 Apr;103(1):54-62.

PMID:
11987985
25.

DNA adducts and liver DNA replication in rats during chronic exposure to N-nitrosodimethylamine (NDMA) and their relationships to the dose-dependence of NDMA hepatocarcinogenesis.

Souliotis VL, Henneman JR, Reed CD, Chhabra SK, Diwan BA, Anderson LM, Kyrtopoulos SA.

Mutat Res. 2002 Mar 20;500(1-2):75-87.

PMID:
11890936
26.
27.

DNA adducts, mutant frequencies and mutation spectra in lambda lacZ transgenic mice treated with N-nitrosodimethylamine.

Souliotis VL, van Delft JH, Steenwinkel MJ, Baan RA, Kyrtopoulos SA.

Carcinogenesis. 1998 May;19(5):731-9.

PMID:
9635857
28.

Effects of 2-chlorodeoxyadenosine and gold sodium thiomalate on human bcl-2 gene expression.

Sfikakis PP, Dimopoulos MA, Souliotis VL, Charalambopoulos D, Mavrikakis M, Panayiotidis P.

Immunopharmacol Immunotoxicol. 1998 Feb;20(1):63-77.

PMID:
9543700
29.

A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine.

Saunders MP, Salisbury AJ, O'Byrne KJ, Souliotis VL, Varcoe SM, Talbot DC, Kyrtopoulos SA, Harris AL.

Anticancer Res. 1997 Nov-Dec;17(6D):4677-80.

PMID:
9494588
30.

DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance.

Kyrtopoulos SA, Anderson LM, Chhabra SK, Souliotis VL, Pletsa V, Valavanis C, Georgiadis P.

Cancer Detect Prev. 1997;21(5):391-405. Review.

PMID:
9307842
31.

Regulation of bcl-2 and fas expression in primary activation of human peripheral lymphocytes is not sensitive to dexamethasone or cyclosporin-A.

Sfikakis PP, Souliotis VL, Akbar AN, Katsilambros N, Hoffbrand VA, Panayiotidis P.

Hum Immunol. 1996 Oct;50(2):121-6.

PMID:
8891735
32.

DNA damage studies related to the assessment of the role of N-nitroso compounds in human cancer.

Kyrtopoulos SA, Souliotis VL, Chhabra SK, Anderson LM.

Eur J Cancer Prev. 1996 Sep;5 Suppl 1:109-14. Review. No abstract available.

PMID:
8972304
33.

Biomonitoring human exposure to environmental carcinogenic chemicals.

Farmer PB, Sepai O, Lawrence R, Autrup H, Sabro Nielsen P, Vestergård AB, Waters R, Leuratti C, Jones NJ, Stone J, Baan RA, van Delft JH, Steenwinkel MJ, Kyrtopoulos SA, Souliotis VL, Theodorakopoulos N, Bacalis NC, Natarajan AT, Tates AD, Haugen A, Andreassen A, Ovrebø S, Shuker DE, Amaning KS, Castelain P, et al.

Mutagenesis. 1996 Jul;11(4):363-81.

PMID:
8671761
34.

Nitrosamines, alcohol, and gastrointestinal tract cancer: recent epidemiology and experimentation.

Chhabra SK, Souliotis VL, Kyrtopoulos SA, Anderson LM.

In Vivo. 1996 May-Jun;10(3):265-84. Review.

PMID:
8797028
35.

Comparative study of the formation and repair of O6-methylguanine in humans and rodents treated with dacarbazine.

Souliotis VL, Valavanis C, Boussiotis VA, Pangalis GA, Kyrtopoulos SA.

Carcinogenesis. 1996 Apr;17(4):725-32.

PMID:
8625483
36.

Downregulation of interleukin-2 and apha-chain interleukin-2 receptor biosynthesis by cisplatin in human peripheral lymphocytes.

Sfikakis PP, Souliotis VL, Katsilambros N, Markakis K, Vaiopoulos G, Tsokos GC, Panayiotidis P.

Clin Immunol Immunopathol. 1996 Apr;79(1):43-9.

PMID:
8612350
37.

N-nitrosodimethylamine-derived O(6)-methylguanine in DNA of monkey gastrointestinal and urogenital organs and enhancement by ethanol.

Anderson LM, Souliotis VL, Chhabra SK, Moskal TJ, Harbaugh SD, Kyrtopoulos SA.

Int J Cancer. 1996 Mar 28;66(1):130-4.

38.

Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.

Philip PA, Souliotis VL, Harris AL, Salisbury A, Tates AD, Mitchell K, van Delft JH, Ganesan TS, Kyrtopoulos SA.

Clin Cancer Res. 1996 Feb;2(2):303-10.

39.

Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine.

Bianchini F, Weiderpass E, Kyrtopoulos S, Souliotis VL, Henry-Amar M, Wild CP, Boffetta P.

Biomarkers. 1996;1(4):226-31. doi: 10.3109/13547509609079362.

PMID:
23888989
40.

N7-Methylguanine and O(6)-methylguanine levels in DNA of white blood cells from cancer patients treated with dacarbazine.

van Delft JH, Luiten-Schuite A, Souliotis VL, Kyrtopoulos SA, Ouwerkerk J, Keizer HJ, Baan RA.

Biomarkers. 1996;1(2):94-8. doi: 10.3109/13547509609088676.

PMID:
23888919
41.

O6-methylguanine DNA adduct formation and modulation by ethanol in placenta and fetal tissues after exposure of pregnant patas monkeys to N-nitrosodimethylamine.

Chhabra SK, Souliotis VL, Harbaugh JW, Krasnow SW, Jones AB, Anderson LM, Kyrtopoulos SA.

Cancer Res. 1995 Dec 15;55(24):6017-20.

42.
43.

Alcohol-related cancer risk: a toxicokinetic hypothesis.

Anderson LM, Chhabra SK, Nerurkar PV, Souliotis VL, Kyrtopoulos SA.

Alcohol. 1995 Mar-Apr;12(2):97-104. Review.

PMID:
7772272
44.

Comparative study of mutagenesis by O6-methylguanine in the human Ha-ras oncogene in E. coli and in vitro.

Pletsa V, Troungos C, Souliotis VL, Kyrtopoulos SA.

Nucleic Acids Res. 1994 Sep 25;22(19):3846-53.

45.

Comparative dosimetry of O6-methylguanine in humans and rodents treated with procarbazine.

Souliotis VL, Valavanis C, Boussiotis VA, Pangalis GA, Kyrtopoulos SA.

Carcinogenesis. 1994 Aug;15(8):1675-80.

PMID:
8055650
48.

Accumulation of O6-methylguanine in human DNA after therapeutic exposure to methylating agents and its relationship with biological effects.

Kyrtopoulos SA, Souliotis VL, Valavanis C, Boussiotis VA, Pangalis GA.

Environ Health Perspect. 1993 Mar;99:143-7.

49.
50.

Measurement of O6-methylguanine-type adducts in DNA and O6-alkylguanine-DNA-alkyltransferase repair activity in normal and neoplastic human tissues.

Souliotis VL, Zongza V, Nikolopoulou V, Dimitriadis GJ.

Comp Biochem Physiol B. 1992 Jan-Feb;101(1-2):269-75.

PMID:
1499274

Supplemental Content

Loading ...
Support Center